NO991425L - Medisinsk behandling - Google Patents

Medisinsk behandling

Info

Publication number: NO991425L
Authority: NO; Norway
Prior art keywords: medical treatment; hyperuricaemia; methylbutyl; monohydrate; cyclobutyl
Prior art date: 1996-09-25

Application number

NO991425A

Other languages

English (en)

Norwegian (no)

Other versions

NO991425D0 (no

Inventor

Peter Finian Kelly

Stephen Paul Jones

Original Assignee

Knoll Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-25

Filing date

1999-03-24

Publication date

1999-03-24

1999-03-24 Application filed by Knoll Ag filed Critical Knoll Ag

1999-03-24 Publication of NO991425D0 publication Critical patent/NO991425D0/no

1999-03-24 Publication of NO991425L publication Critical patent/NO991425L/no

Links

125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
201000005569 Gout Diseases 0.000 abstract 1
201000001431 Hyperuricemia Diseases 0.000 abstract 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000029078 coronary artery disease Diseases 0.000 abstract 1
150000004682 monohydrates Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229940116269 uric acid Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Materials For Medical Uses (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Crystals, And After-Treatments Of Crystals (AREA)

NO991425A 1996-09-25 1999-03-24 Medisinsk behandling NO991425L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9619962.5A GB9619962D0 (en)	1996-09-25	1996-09-25	Medical treatment
PCT/EP1997/005034 WO1998013033A1 (en)	1996-09-25	1997-09-15	Medical treatment

Publications (2)

Publication Number	Publication Date
NO991425D0 NO991425D0 (no)	1999-03-24
NO991425L true NO991425L (no)	1999-03-24

Family

ID=10800448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO991425A NO991425L (no)	1996-09-25	1999-03-24	Medisinsk behandling

Country Status (26)

Country	Link
US (1)	US6162831A (de)
EP (1)	EP1007023B1 (de)
JP (1)	JP2001501608A (de)
KR (1)	KR20000048568A (de)
CN (1)	CN1231604A (de)
AT (1)	ATE239460T1 (de)
AU (1)	AU722129B2 (de)
BG (1)	BG103278A (de)
BR (1)	BR9711414A (de)
CA (1)	CA2266438A1 (de)
DE (1)	DE69721838T2 (de)
DK (1)	DK1007023T3 (de)
ES (1)	ES2199374T3 (de)
GB (1)	GB9619962D0 (de)
HR (1)	HRP970519A2 (de)
HU (1)	HUP9904545A3 (de)
IL (1)	IL128851A (de)
NO (1)	NO991425L (de)
NZ (1)	NZ334668A (de)
PL (1)	PL332423A1 (de)
PT (1)	PT1007023E (de)
SK (1)	SK32199A3 (de)
TR (1)	TR199900649T2 (de)
TW (1)	TW415842B (de)
WO (1)	WO1998013033A1 (de)
ZA (1)	ZA978573B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6331571B1 (en)	1998-08-24	2001-12-18	Sepracor, Inc.	Methods of treating and preventing attention deficit disorders
US6339106B1 (en)	1999-08-11	2002-01-15	Sepracor, Inc.	Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en)	1999-08-11	2002-11-05	Sepracor, Inc.	Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en)	1998-08-24	2005-12-13	Sepracor Inc.	Methods of treating or preventing pain using sibutramine metabolites
US6552087B1 (en)	1999-03-19	2003-04-22	Abbott Gmbh & Co. Kg	Therapeutic agent comprising (+)-sibutramine
PL365463A1 (en) *	1999-03-19	2005-01-10	Knoll Gmbh	Treatment of osteoarthritis
US6399826B1 (en)	1999-08-11	2002-06-04	Sepracor Inc.	Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en)	2001-04-13	2002-10-24	Sepracor Inc.	Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US11103542B2 (en)	2002-03-13	2021-08-31	Kibow Biotech, Inc.	Composition and method for maintaining healthy kidney function
US9655932B2 (en) *	2002-03-13	2017-05-23	Kibow Biotech, Inc.	Composition and method for preventing or treating gout or hyperuricemia
NZ538966A (en) *	2002-10-05	2006-11-30	Hanmi Pharm	Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) *	2003-08-04	2005-06-16	Beckman Kristen M.	Methods for treating metabolic syndrome
WO2006012438A2 (en) *	2004-07-21	2006-02-02	University Of Florida Research Foundation, Inc.	Compositions and methods for treatment and prevention of insulin resistance
KR100627687B1 (ko) *	2005-04-20	2006-09-25	주식회사 씨티씨바이오	시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR20080046601A (ko) *	2006-11-22	2008-05-27	에스케이케미칼주식회사	보관안정성이 우수한 시부트라민 함유 포접복합체
US11179426B2 (en)	2016-12-29	2021-11-23	Kibow Biotech, Inc.	Composition and method for maintaining healthy kidney function
US20210369769A1 (en) *	2018-11-02	2021-12-02	Dyve Biosciences, Inc.	Management of risk of cation overload and electrolyte imbalance with topically applied buffers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE52768B1 (en) *	1981-04-06	1988-02-17	Boots Co Ltd	1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) *	1985-12-17	1986-01-29	Boots Co Plc	Therapeutic compound
GB8704777D0 (en) *	1987-02-28	1987-04-01	Boots Co Plc	Medical treatment
JP2675573B2 (ja) *	1988-03-31	1997-11-12	科研製薬株式会社	脳機能改善剤
IE61928B1 (en) *	1988-11-29	1994-11-30	Boots Co Plc	Treatment of obesity
CA2138998A1 (en) *	1992-06-23	1994-01-06	James W. Young	Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
CA2139000A1 (en) *	1992-06-23	1994-01-06	James W. Young	Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
US5459164A (en) *	1994-02-03	1995-10-17	Boots Pharmaceuticals, Inc.	Medical treatment

1996
- 1996-09-25 GB GBGB9619962.5A patent/GB9619962D0/en active Pending
1997
- 1997-09-15 CN CN97198232A patent/CN1231604A/zh active Pending
- 1997-09-15 NZ NZ334668A patent/NZ334668A/xx unknown
- 1997-09-15 JP JP10515217A patent/JP2001501608A/ja active Pending
- 1997-09-15 BR BR9711414-6A patent/BR9711414A/pt not_active Application Discontinuation
- 1997-09-15 DE DE69721838T patent/DE69721838T2/de not_active Expired - Fee Related
- 1997-09-15 TR TR1999/00649T patent/TR199900649T2/xx unknown
- 1997-09-15 PT PT97942030T patent/PT1007023E/pt unknown
- 1997-09-15 DK DK97942030T patent/DK1007023T3/da active
- 1997-09-15 KR KR1019990702491A patent/KR20000048568A/ko not_active Ceased
- 1997-09-15 US US09/269,339 patent/US6162831A/en not_active Expired - Fee Related
- 1997-09-15 AT AT97942030T patent/ATE239460T1/de not_active IP Right Cessation
- 1997-09-15 AU AU43851/97A patent/AU722129B2/en not_active Ceased
- 1997-09-15 PL PL97332423A patent/PL332423A1/xx unknown
- 1997-09-15 ES ES97942030T patent/ES2199374T3/es not_active Expired - Lifetime
- 1997-09-15 IL IL12885197A patent/IL128851A/xx not_active IP Right Cessation
- 1997-09-15 CA CA002266438A patent/CA2266438A1/en not_active Abandoned
- 1997-09-15 EP EP97942030A patent/EP1007023B1/de not_active Expired - Lifetime
- 1997-09-15 WO PCT/EP1997/005034 patent/WO1998013033A1/en not_active Ceased
- 1997-09-15 HU HU9904545A patent/HUP9904545A3/hu unknown
- 1997-09-15 SK SK321-99A patent/SK32199A3/sk unknown
- 1997-09-25 ZA ZA978573A patent/ZA978573B/xx unknown
- 1997-09-25 HR HR9619962.5A patent/HRP970519A2/hr not_active Application Discontinuation
- 1997-09-25 TW TW086113992A patent/TW415842B/zh not_active IP Right Cessation
1999
- 1999-03-24 NO NO991425A patent/NO991425L/no unknown
- 1999-03-24 BG BG103278A patent/BG103278A/xx unknown

Also Published As

Publication number	Publication date
WO1998013033A1 (en)	1998-04-02
NO991425D0 (no)	1999-03-24
AU722129B2 (en)	2000-07-20
ZA978573B (en)	1999-03-25
NZ334668A (en)	2000-07-28
EP1007023B1 (de)	2003-05-07
CN1231604A (zh)	1999-10-13
IL128851A (en)	2001-08-26
EP1007023A1 (de)	2000-06-14
PL332423A1 (en)	1999-09-13
DE69721838T2 (de)	2004-01-22
BR9711414A (pt)	2000-04-25
TR199900649T2 (xx)	1999-07-21
SK32199A3 (en)	1999-12-10
CA2266438A1 (en)	1998-04-02
BG103278A (en)	2000-01-31
PT1007023E (pt)	2003-08-29
ES2199374T3 (es)	2004-02-16
IL128851A0 (en)	2000-01-31
HUP9904545A3 (en)	2000-12-28
KR20000048568A (ko)	2000-07-25
AU4385197A (en)	1998-04-17
TW415842B (en)	2000-12-21
GB9619962D0 (en)	1996-11-13
HRP970519A2 (en)	1998-08-31
HUP9904545A2 (hu)	2000-11-28
ATE239460T1 (de)	2003-05-15
DK1007023T3 (da)	2003-08-25
JP2001501608A (ja)	2001-02-06
US6162831A (en)	2000-12-19
DE69721838D1 (de)	2003-06-12

Publication	Publication Date	Title
NO991425L (no)	1999-03-24	Medisinsk behandling
PH31220A (en)	1998-05-05	Medical treatment.
ID21775A (id)	1999-07-22	Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
NO20021328L (no)	2002-05-21	Pyrazolopyrimidier som terapeutiske midler
NO20001515L (no)	2000-03-23	Vitronektin reseptor-antagonist
DE60220055D1 (de)	2007-06-21	4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
WO2003031447A3 (de)	2003-08-28	Pyrimidinderivate mit pde-v hemmender wirkung
BR0009080A (pt)	2002-02-13	Método de tratamento da apnéia do sono
NZ220779A (en)	1989-09-27	4-(aroylamino) piperidine butanamides, intermediates, and compositions
NO923532L (no)	1993-03-15	4-(4-(4-(4-hydroksyfenyl)-piperazinyl)fenyl)-5-metyl-3h-1,2,4-triazol-3-on-derivater
GR3004848T3 (de)	1993-04-28
NO170014C (no)	1992-09-02	Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse (3s(z))-2-(((1-(2-amino-4-tiazolyl)-2-((2,2-dimetyl-4-okso-1-(sulfooksy)-3-azetidinyl)amino)-2-oksoetyliden)amino)oksy)-eddiksyre
NO983453L (no)	1998-09-11	Fremgangsmåte for ökning av sfinkterfunksjon
NO20016301L (no)	2001-12-21	Terapeutiske midler
ATE44875T1 (de)	1989-08-15	4-amino-2-(imidazolidin-2-on-l-yl)-pyrimidin-5carbons\|ure-(n-(3-trifluormethyl-phenyl)-amide) zur antithrombotischen prophylaxe und behandlung sowie ihre verwendung zur herstellung von antithrombotisch wirksamen arzneimitteln.
MXPA01009468A (es)	2004-03-19	Tratamiento de hipertension pulmonar.
RU99108729A (ru)	2001-02-20	Способ лечения